Atripla to Stribild Switch Study to Evaluate Sleep Disturbances
- Registration Number
- NCT02477527
- Lead Sponsor
- Midtown Medical Center, Tampa, FL
- Brief Summary
Switch patients from Atripla to Stribild will be evaluated to see if patients have less sleep disturbances.
- Detailed Description
Stribild is a preferred regimen in the Department of Health and Human Services guidelines and has demonstrated non-inferiority to Atripla in treatment naïve patients out to 144 weeks (GS-102). Stribild also has statistically significant less Central Nervous System side effects, sleep disturbances and lipid elevations compared to Atripla. This study will evaluate the efficacy, safety, changes in Central Nervous System abnormalities and sleep disorders following a switch from virologically suppressed subjects on Atripla to Stribild.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
- HIV+ subjects 18 years of age or older
- estimated Glomerular Filtration Rate > 70 mL/min
- must currently be on Atripla and taking it for at least 3 months with a HIV-1 Viral Load < 50 copies/mL
- no antiretrovirals prior to the initiation of Atripla
- baseline genotyping
- pregnancy
- unable to provide informed consent
- enrolled in another study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Stribild Stribild Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.
- Primary Outcome Measures
Name Time Method Percentage of Patients With Viral Loads < 50 Following the Switch 24 weeks percentage of patients with viral loads \< 50 following the switch at 24 weeks.
- Secondary Outcome Measures
Name Time Method T-cell Changes 24 weeks Change in CD4 Cell count from baseline to 24 weeks.
Improvements in Central Nervous System Toxicity Score 24 weeks Changes in Central Nervous System toxicity score at week 24 as measured by SSAT 047 scale.
The scale is a questionnaire that participants complete at each visit. The SSAT 047 scores 10 items related to efavirenz side effects including: dizziness, depression, insomnia, anxiety, confusion, impaired concentration, headache, somnolence, aggressive mood and abnormal dreams. The side effects were scored as 0 for "None", 1 for "Mild", 2 for "Moderate" and 3 for "Severe". The scores for the 10 items ranged from 0(none) - 3(severe), and the total score is 0-30. The scores are then averaged to determine the overall impact on central nervous system symptoms and reported as the sum of the measures.Improvements in Sleep Disorder Score 24 weeks Changes in quality of sleep at week 24 as measured by Pittsburgh Sleep Quality Index (PSQI). The Pittsburgh Sleep Quality Index (PSQI) is used to measure the quality and patterns of sleep in adults. It rates sleep based on seven domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month. It is a self-administered questionnaire covering these seven areas of sleep. Scoring of the answers is based on a 0 to 3 scale, whereby 3 reflects the negative extreme on the Likert Scale. The scores for the 7 items ranged from 0(none) - 3(severe), and the total score is 0-21. The reported values in the table represent the change in the overall scores on the PSQI scale. The values were added and reported as the sum of the individual measures. A negative score correlates with improvement of the sleep quality.